Affinity Groups

There are no Affinity Groups associated with this topic. View All Affinity Groups.

Topics from Ask.CI

Loading topics from Ask.CI...

Knowledge Base Resources

Engagements

Re-engineering Lilly’s KisunlaTM into a novel antibody targeting IL13RA2 against GBM using AI-driven macromolecular modeling
Atrium Health Levine Cancer
  • Summary and objectives of the proposed experiments: 
  1. An initial research-based Ab (scFv47, discovered by our collaborator Dr. Balyasnikova) model, modeling Ab-Ag (IL13RA2 against GBM) protein complex, and identifying the binding sites (epitopes) using ROSETTA and AlphaFold2 multimer tools.
  2. Graft the CDRs of scFv (single-chain variable fragment) of antibody or Bispecific T cell engagers (BTEs) onto the template Ab, the framework of Lilly's Kisunla™ Ab drug.
  3. Modify, improve, and optimize the overall or full antibody protein structures using AI-driven macromolecule modeling (AlphaFold3).
  4. Explore single nucleotide polymorphism (SNP), pathogenic genetic variants and N-glycosylation of IL13RA2 (target) protein domain interacting with the Ab candidates among the patient population using ROSETTA software packages.
Status: In Progress

People with Expertise

Craig Earley

University of Colorado Boulder

Programs

RMACC

Roles

mentor

Placeholder headshot

Expertise

Jason Simms

Swarthmore College

Programs

ACCESS CSSN, Campus Champions, CCMNet

Roles

CampusChampionsAdmin, research computing facilitator, cssn, Affinity Group Leader, CCMNet

Jason Simms Headshot

Expertise

Lakitha Wijeratne

The University of Texas at Dallas

Programs

TRECIS

Roles

mentor, researcher/educator

Expertise

People with Interest

Sanju Timsina

Programs

CCMNet

Roles

CCMNet

S graphic

Interests

Parameshwaran Pasupathy

Rutgers, the State University of New Jersey

Programs

ACCESS CSSN, CAREERS, CCMNet

Roles

student-facilitator, CCMNet

Placeholder headshot

Interests

Matthew Chung

University of California Riverside

Programs

Campus Champions

letter_m

Interests